Ten years of commitment to persons living with HIV-AIDS: Evaluation of the management in three ambulatory treatment centers of the French Red Cross in Africa;Dix ans d'engagement auprès des personnes vivant avec le VIH-sida: Évaluation de la prise en charge dans trois centres de traitement ambulatoire de la Croix-Rouge française en Afrique

Cahiers Sante

Volumn 18, Issue 2, 2008, Pages 89-95

  Mouala, C ^a   Madec, Y ^b   Adam, G ^a   Courpotin, C ^a   Fikouma, V ^c   Gentilini, M ^d   Mohamedoune, A Ould ^e   Nzounza, P ^f   Schaer, E ^g   Simon, B ^a   Mattei, J F ^a  

^a Croix Rouge Française ^*  (France)

^b INSTITUT PASTEUR   (France)

^c Centre de Traitement Ambulatoire   (France)

^d Organisation Panafricaine de Lutte Contre le Sida   (France)

^e Centre de Traitement Ambulatoire   (Mauritania)

^f Centre de Traitement Ambulatoire   (Congo)

^g Association Aider Afrique   (France)

Author keywords

Africa; AIDS; Antiretroviral therapy; CD4+; French red cross; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICA; AMBULATORY CARE; ARTICLE; BLOOD; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; EVALUATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MORTALITY; PRIMARY HEALTH CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RED CROSS; STATISTICAL ANALYSIS; TIME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICA; AMBULATORY CARE; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DATA INTERPRETATION, STATISTICAL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; FRANCE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RED CROSS; TIME FACTORS;

EID: 60249083142     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: 10.1684/san.2008.0117     Document Type: Article

References (25)

1. Croix-Rouge francaise. Lutte contre le VIH-sida: rapport d'activités 2007. 2 novembre 2008 (http ://www.croix-rouge.fr/goto/ actualites/2008/sida-rapport-2007.pdf).
2. Mouala C, Roux P, Okome M, et al. Assessment of compliance with ARV treatment in Africa. Med Trop (Mars) 2006; 66 : 610-4.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Geneva : World Health Organisation, 2006.
4. Libaudière C, Sibille B, Bakala N, et al. Drug supply for HIV patients in day care centre in Republic of Congo : the French Red Cross experience. Med Trop (Mars) 2006; 66 : 598-601.
5. Gentilini M, Chièze F. L'Opals et les centres de traitement ambulatoire du sida en Afrique : I'art et I'urgence du possible. Montrouge : John Libbey ed., 1999.
6. Kumar S. India's treatment programme for AIDS is premature. BMJ 2004; 328 : 70.
7. Loewenson R, McCoy D. Access to antiretroviral treatment in Africa. BMJ 2004; 328 : 241-2.
8. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon : open-label multicenter trial. Lancet 200a; 364: 29-34.
9. Yazdanpanah Y, Sissoko D, Egger M, Mouton Y, Zwahlen M, Chene G. Clinical efficacy of antiretroviral combination therapy-based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors : indirect comparison of controlled trials. BMJ 2004; 328 : 249.
10. Kouanfack C, Laurent C, Peytavin G, et al. Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. J Acquir Immune Defic Syndr 2008; 48 : 216-9.
11. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine : a randomised open-label trial, the 2NN Study team. Lancet 2004; 363 : 1253-63.
12. Laurent C, Diakhaté N, Gueye NF, et al.The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16 :1363-70.
13. WeidlePJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda : patients' response, survival, and drug resistance. Lancet 2002; 360 :34-40.
14. CoetzeeD, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18: 887-95.
15. Idigbe EO, Adewole TA, Eisen G, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine : a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005; 40 : 65-9.
16. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins sans frontières. AIDS 2003; 17 : 1995-7.
17. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003;17 : 2267-9.
18. Cascade Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355 : 1158-9.
19. Detels RMA, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration, Multicenter Aids Cohort Study Investigators. JAMA 1998; 280 : 1497-503.
20. Hanson DL, Chu SY, Farizo KM, Ward JW. Distribution of CD4+ T lymphocytes at diagnosis of acquired immunodeficiency syndrome- defining and other human immunodeficiency virus-related illnesses, The Adult and Adolescent Spectrum of HIV Disease Project Group. Arch Intern Med 1995; 155 : 1537-42.
21. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286 : 2568-77.
22. Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts < 350 cells/microL. Clin Infect Dis 2003; 37 : 951-8.
23. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21 : 2483-91.
24. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol 2008; 168 : 532-40.
25. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126 : 946-54.